华兰股份公告，公司于2025年9月26日召开第六届董事会第六次会议，审议通过了《关于公司投资设立 全资子公司的议案》。公司将使用自有资金人民币5000万元在海南省投资设立全资子公司，主要经营范 围为人工智能创新药研发解决方案及服务。此举符合公司战略布局和产业发展需要，旨在拓展新业务增 长点，促进公司健康发展。投资不构成关联交易或重大资产重组，且不会对公司财务状况和经营成果产 生重大影响。 ...

每经AI快讯，9月26日，华兰股份（301093）(301093.SZ)公告称，公司拟使用自有资金5000万元在海南 省投资设立全资子公司，主要经营范围为人工智能创新药研发解决方案及服务。该投资旨在发展公司新 的业务增长点，扩大影响力，促进公司健康发展。同时，公司将对全资子公司进行统筹规划，充分发挥 协同效应，实现优势互补，拓宽业务范围与市场领域。 ...

Group 1 - The company plans to invest RMB 50 million to establish a wholly-owned subsidiary in Hainan Province for the development of artificial intelligence innovative drug research and development solutions and services [1] - In November 2024, the National Health Commission will release guidelines that promote the application of "artificial intelligence+" in drug development, aiming to advance innovation in the health industry [1]

证券代码：301093 证券简称：华兰股份 公告编号：2025-099 江苏华兰药用新材料股份有限公司 关于公司投资设立全资子公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本次投资概述 江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司"）于 2025 年 9 月 26 日召开第六届董事会第六次会议，审议通过了《关于公司投资设 立全资子公司的议案》。根据公司战略布局和产业发展的需要，公司拟使用自有 资金人民币 5,000 万元在海南省投资设立全资子公司，该全资子公司的主要经 营范围为：人工智能创新药研发解决方案及服务（具体经营范围以全资子公司 取得的营业执照记载为准）。同时董事会授权公司核心管理层办理本次全资子公 司的工商登记等相关事宜。 （一）企业名称：以工商最终核准的名称为准 （二）企业类型：有限责任公司 （三）企业住所：海南省（以工商最终核准的信息为准） （四）注册资本：人民币 5,000 万元 （五）经营范围：人工智能创新药研发解决方案及服务（具体经营范围以 全资子公司取得的营业执照记载为准）。 （六）股权结构：公司持有其 ...

证券代码：301093 证券简称：华兰股份 公告编号：2025-097 江苏华兰药用新材料股份有限公司 2、会议以 7 票同意、2 票反对、0 票弃权，审议通过了《关于公司投资设 立全资子公司的议案》。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）上披露的《关 于公司投资设立全资子公司的公告》。 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司"）第 六届董事会第六次会议通知于 2025 年 9 月 22 日以邮件、电话等方式向各位董 事发出，会议于 2025 年 9 月 26 日以现场会议结合通讯形式召开。本次会议由 公司董事长华一敏先生召集并主持，应出席会议的董事 9 人，实际出席会议的 董事 9 人，其中华国平先生、崔珂女士、姚茗芳女士、单体超先生、陈岗先生、 刘力先生、侯绪超先生以通讯表决方式出席本次董事会会议，公司高级管理人 员列席了会议。本次会议的召集、召开及表决符合《公司法》等有关法律、法 规、规范性文件 ...

关于调整公司组织架构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2025 年 9 月 26 日，江苏华兰药用新材料股份有限公司（以下简称"公司"） 第六届董事会第六次会议审议通过了《关于调整公司组织架构的议案》。根据公 司战略发展需求及实际经营情况，为进一步完善公司治理结构，优化管理流程， 提高公司管理水平和运营效率。董事会同意公司对组织架构进行优化调整，调 整后的公司组织架构图详见附件。 特此公告。 证券代码：301093 证券简称：华兰股份 公告编号：2025-098 江苏华兰药用新材料股份有限公司 江苏华兰药用新材料股份有限公司董事会 2025 年 9 月 26 日 附件 江苏华兰药用新材料股份有限公司组织架构图 ...

Group 1 - On September 25, Hualan Co., Ltd. experienced a slight increase of 0.11% in stock price, with a trading volume of 382 million yuan [1] - The financing data for Hualan on the same day showed a financing purchase amount of 48.17 million yuan and a net financing purchase of 8.96 million yuan, with a total financing and securities balance of 513 million yuan [1] - The financing balance of Hualan accounts for 6.98% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, Hualan had 15,300 shareholders, a decrease of 1.05% from the previous period, while the average circulating shares per person increased by 38.20% to 7,901 shares [2] - For the first half of 2025, Hualan reported an operating income of 309 million yuan, representing a year-on-year growth of 8.82%, and a net profit attributable to shareholders of 43.73 million yuan, up 18.27% year-on-year [2] Group 3 - Hualan has distributed a total of 238 million yuan in dividends since its A-share listing, with 144 million yuan distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders of Hualan saw the exit of Changjiang Intelligent Manufacturing Mixed Fund from the list [3]

Market Overview - On September 24, the medical device sector rose by 0.1% compared to the previous trading day, with Hualan Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Top Performers - Hualan Co., Ltd. (301093) closed at 44.74, up 10.20% with a trading volume of 120,900 shares and a transaction value of 526 million yuan [1] - Huitai Medical (688617) closed at 321.65, up 6.86% with a trading volume of 21,200 shares [1] - Jinhao Medical (872925) closed at 31.15, up 6.68% with a trading volume of 17,400 shares [1] Other Notable Stocks - Dongxing Medical (301290) closed at 27.96, up 5.35% with a trading volume of 34,600 shares [1] - Dabo Medical (002901) closed at 55.06, up 5.02% with a trading volume of 42,100 shares [1] - Maike Aodi (300341) closed at 18.79, up 4.97% with a trading volume of 373,300 shares [1] Fund Flow Analysis - The medical device sector experienced a net outflow of 12.47 million yuan from institutional investors, while retail investors saw a net inflow of 24.3 million yuan [2] - The overall fund flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Fund Flow - Maike Aodi (300341) had a net inflow of 94.47 million yuan from institutional investors, but a net outflow of 85.20 million yuan from retail investors [3] - Huo Jing Biological (688068) saw a net inflow of 58.76 million yuan from institutional investors, with retail investors also withdrawing funds [3] - Dabo Medical (002901) had a net inflow of 33.73 million yuan from institutional investors, while retail investors experienced a net outflow [3]

Group 1 - The core viewpoint of the news is that Hualan Co., Ltd. has seen a 5% increase in stock price, reaching 42.63 yuan per share, with a total market capitalization of 7 billion yuan [1] - Hualan Co., Ltd. specializes in the research, production, and sales of packaging materials for injectable drugs, with its main revenue sources being film-coated rubber stoppers (49.07%) and conventional rubber stoppers (48.50%) [1] - The company was established on June 4, 1992, and went public on November 1, 2021 [1] Group 2 - According to data, Dachen Fund has a significant holding in Hualan Co., Ltd., with its Dachen Growth Mixed Fund holding 620,000 shares, accounting for 3.29% of the fund's net value [2] - The Dachen Growth Mixed Fund has achieved a year-to-date return of 23.45% and a one-year return of 46.55% [2] - The fund manager, Zou Jian, has been in position for 4 years and 243 days, with the fund's total asset size currently at 1.086 billion yuan [2]

Group 1 - The stock price of Hualan Biological Engineering reached a historical high, increasing by 4.85% to 42.57 yuan, with a trading volume of 2.7837 million shares and a transaction value of 115 million yuan, resulting in a turnover rate of 1.77% [2] - The latest total market capitalization of Hualan Biological is 6.99 billion yuan, with a circulating market capitalization of 6.681 billion yuan [2] - The pharmaceutical and biotechnology industry, to which Hualan belongs, has an overall increase of 0.48%, with 377 stocks rising, including notable gainers such as Sunflower, Ganli Pharmaceutical, and Xinlitai, which rose by 15.13%, 8.97%, and 6.83% respectively [2] Group 2 - The latest margin trading data shows that Hualan's margin balance is 490 million yuan, with a financing balance of 490 million yuan, which has increased by 42.599 million yuan over the past 10 days, reflecting a growth of 9.52% [2] - According to the company's semi-annual report, Hualan achieved an operating income of 309 million yuan in the first half of the year, representing a year-on-year growth of 8.82%, and a net profit of 43.7321 million yuan, which is an increase of 18.27% year-on-year, with basic earnings per share of 0.2700 yuan and a weighted average return on equity of 1.93% [2]